Place of antibiotics in the schemes of inflammatory intestinal diseases treatment (review of literature)


Cite item

Full Text

Abstract

We discussed the problem of the use of antibacterial drugs in the treatment of inflammatory bowel disease (IBD). The results of numerous studies on the management of combination antibiotic therapy in addition to treatment by glucocorticosteroids, probiotics, chemotherapeutic agents in various forms of IBD are presented. These experimental and clinical data show that not only antibiotics, as follows a complex of several "technical" methods in patients with IBD will allow to control such a complex system as microflora of gastro-intestinal tract with projected effect.

References

  1. Ардатская М.Д., Минушкин О.Н., Прихно Н.И. и др. Летучие жирные кислоты и их диагностическое и прогностическое значение в гастроэнтерологической практике // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2000. Т. 10. № 5. С. 63-70.
  2. Бондаренко В.М., Мацулевич Т.В. Дисбактериоз кишечника как клинико-лабораторный синдром. М., 2007.
  3. Бондаренко В.М., Чуприна Р.П., Воробьева М.А. Механизм действия пробиотических препаратов // Биопрепараты. 2003. № 3. С. 2-5.
  4. Бондаренко В.М., Воробьев А.А. Дисбиозы и препараты с пробиотической функцией // Журнал микробиологии. 2004. № 1. С. 84-92.
  5. Бондаренко В.М., Лиходед В.Г., Яковлев М.Ю. Определение эндотоксина грамотрицательных бактерий в крови человека // Журнал микробиологии. 2002. № 2. С. 83-89.
  6. Вахитов Т.Я., Петров Л.Н., Бондаренко В.М. Концепция пробиотического препарата, содержащего оригинальные микробные метаболиты // Журнал микробиологии. 2005. № 5. С. 108-114.
  7. Григорьев А.В. Бактериальная гистадгезия // Медичний Всесвiт. 2003. Т. 3. № 2. С. 15-22.
  8. Ковальчук Л.В., Долгина Е.Н., Ганковская Л.В. и др. Цитокиновый профиль биологических жидкостей организма человека // Аллергология и иммунология. 2005. Т. 6. № 4. С. 460-464.
  9. Кожевин П.А. Микробные популяции в природе. М., 1989.
  10. Кононов А.В., Миронова О.Н. Гистобактериоскопический и бактериологический методы исследования колонобиоптатов и характеристика пристеночной микрофлоры, как показатель биоценоза толстой кишки. Пособие для врачей. 2005. С. 12-23.
  11. Осипов Г.А. Невидимый орган - микрофлора человека. Lu Novellas esteticques. 2004;3:10-15.
  12. Павлова И.Л., Левченко Е.М. Электронно-микроскопическое исследование адгезивности бактерий. ЖМЭИ. 2002. № 1. С. 1-6.
  13. Тец В.В., Заславская Н.В. Эффективность действия антибиотиков на бактерий в биопленках // Журнал микробиологии. 2005. № 5. С. 24-26.
  14. Шендеров Б.А. Медицинская микробная экология и функциональное питание. М., 1998. Т. 2.
  15. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-29.
  16. Brandt LJ, Berstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-87.
  17. Bamias G, Marini M, Moskaluk CA, et al. Down-regulation of intestinal lymphocyte activation and Th I cytokine production by antibiotic therapy in a murine model of Crohn's disease, J Immunol 2002;169:5308-14.
  18. Colombel JF, Lemann M, Cassagnou M, et al. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999;94:674-78.
  19. Camma C, Viscido A, Latella G, et al. Mesalamine in the prevention of clinical and endoscopic post-operative recurrence of Crohn's disease: a meta-analysis. Dig Liver Dis 2002;34:A86.
  20. Campieri M, Rizzello F, Vcnturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study versus mesalazine. Gastroenterology 2000;118(Suppl. 1):A781.
  21. Dejaco C, Harrer M, Wealthier T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003;18:1113-1120.
  22. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
  23. Fukuda M, Kanauchi O, Araki Y, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med 2002;9:65-70.
  24. Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003;98:2363-71.
  25. Gilat T, Leichtman G, Delpre G, et al. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 1989;11:392-95.
  26. Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49(3):467-84.
  27. Gionchetti P, Rizzello F, Morselli C, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007;25:1231-36.
  28. Gionchetti P, Rizzcllo F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-21.
  29. Gionchetti P, Rizzcllo F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713-18.
  30. Greenfield C, Aguilar-Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut 1983;24:713-17.
  31. Guslandi M, Giollo P, Testoni PA. Corticoste-roid-sparing effect of rifaximin, a nonabsorbable oral antibiotic in active ulcerative colitis: Preliminary clinical experience. Curr Ther Res 2004;65:292-96.
  32. Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-84.
  33. Hoentjen F, Harmstan HJ, Brant H, et al. Antibodies with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in IL-10 deficient mice, Gut 2003;52(12):1721-27.
  34. Hans W, Scholmerich J, Gross V, et al. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur J Gastroenterol Hepatol 2000;12:267-73.
  35. Kallinowski F, Wassmer A, Hofmann MA, et al. Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Hepatogastroenterology 1998;45:1552-58.
  36. Kochhar R, Ayyagari A, Goenka MK, et al. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol 1993;16:26-30.
  37. Konstantinov SR, Fitzsimons N, Vaughan EE, et al. From composition to functionality of the intestinal microbial communities. In: Tannock GW, ed. Probiotics and prebiotics: where are we going? Wymondham, UK: Caister Academic Press 2002:59-84.
  38. Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology 2002;122(Suppl. 1):A434.
  39. Mishkin D, Boston FM, Blank D, et al. The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease. Dig Dis Sci 2002;47:489-94.
  40. Mimura T, Rizzello F, Helwig U, et al. Four week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-17.
  41. Neut C, Bulois R Desreumaux P, et at. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002;97:939-46.
  42. Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005;40:1334-42.
  43. Onderdonk AB, HermosJ A, Dzink JL, et al. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978;74:521-26.
  44. Panwala CM, Jones JC, VineyJL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr I a, spontaneously develop colitis. J Immunol 1998;161:5733-44.
  45. Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12:651-64.
  46. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
  47. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23(8):1117-25.
  48. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.
  49. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
  50. Rutgeerts P, Assche GV, Vermeire S, et al. Ornidazole for prophylaxis of post-operative Crohn's disease: a randomized, double blind, placebocontrolled trial. Gastroenterology 2005;128:856-61.
  51. Roediger WE, DuncanA, Kapanins Oetal, Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 1993;104:802-09.
  52. Sartor RB. Microbial agents in the pathogenesis, differential diagnosis, and complications of inflammatory bowel diseases. In: Bfaseri MJ, Smith PD, Ravdin JI et al, eds. Infections of the gastrointestinal tract, 2nd edn. Philadelphia: Lippincott Williams & Wilkins 2002:383-413.
  53. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 2005;21(8):1165-69.
  54. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-05.
  55. Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007;50:498-508.
  56. Shen B, Remzi FH, Lopez AR, et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterology 2008;8:26-33.
  57. Steinhart AH, Feagan B, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.
  58. Stange EF, Travis SPL, Vermeire S, et al. and for the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of Crohn's disease. Gut 2006;55:1-15.
  59. Sutherland LR, Singleton J, Sessions J, et al. Double-blind, placebocontrolled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-75.
  60. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
  61. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981;80:693-96.
  62. Travis SPL, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis 2008;2:24-62.
  63. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology 1982;83:550-62.
  64. Van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case control study. BMJ 2002;324:1306-07.
  65. Videla S, Vilaseca J, Guarner F, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090-97.
  66. Weber R, Koch M, Heizmann WR, et al. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992;14:302-08.
  67. Yamada T, Deitch E, Specian RD, et al. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-62.
  68. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2366&mid=1085056570&magid=177

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies